{
  "variants": [
    {
      "variant_string_id": "SNCA_E46K",
      "functional_evidence_aim": "Pathogenic",
      "steps": [
        {
          "step": "1. Define the disease mechanism",
          "judgment": "Yes",
          "details": "The E46K mutation increases Î±-synuclein fibrillization propensity, which is directly linked to pathological amyloid formation and disease pathogenesis."
        },
        {
          "step": "2. Evaluate assay applicability",
          "judgment": "Yes",
          "details": "The in vitro polymerization assay models the disease mechanism (aberrant amyloid formation) and is relevant to pathological outcomes."
        },
        {
          "step": "3a. Basic controls and replicates",
          "judgment": "Not explicitly stated",
          "details": "The abstract does not specify controls or replicates, but the study likely included wild-type and other variant comparisons to establish baseline effects."
        },
        {
          "step": "3b. Variant controls",
          "judgment": "Not explicitly stated",
          "details": "The study may have used other variants (e.g., wild-type) as controls, but this is not detailed in the abstract."
        },
        {
          "step": "3c. Correlate OddsPath",
          "judgment": "Not explicitly stated",
          "details": "The abstract does not report OddsPath calculations, but the A53T mutation's greater effect suggests statistical significance."
        },
        {
          "step": "4a. Statistical analyses",
          "judgment": "Not explicitly stated",
          "details": "The abstract mentions increased fibrillization but lacks p-values or effect sizes for OddsPath calculation."
        },
        {
          "step": "4b. Control variant count",
          "judgment": "Unclear",
          "details": "The abstract does not specify the number of benign/pathogenic controls used in the study."
        },
        {
          "step": "4c. OddsPath correlation",
          "judgment": "Not applicable",
          "details": "No direct OddsPath value reported, but the A53T mutation's stronger effect implies a higher pathogenicity likelihood."
        }
      ],
      "strength": "PS3_supporting"
    },
    {
      "variant_string_id": "SNCA_A53T",
      "functional_evidence_aim": "Pathogenic",
      "steps": [
        {
          "step": "1. Define the disease mechanism",
          "judgment": "Yes",
          "details": "The A53T mutation significantly increases fibrillization propensity, directly linking to amyloidopathies and disease progression."
        },
        {
          "step": "2. Evaluate assay applicability",
          "judgment": "Yes",
          "details": "The polymerization assay models the disease mechanism (amyloid formation) and is relevant to pathological outcomes."
        },
        {
          "step": "3a. Basic controls and replicates",
          "judgment": "Not explicitly stated",
          "details": "The abstract does not specify controls or replicates, but the study likely included wild-type and other variant comparisons."
        },
        {
          "step": "3b. Variant controls",
          "judgment": "Not explicitly stated",
          "details": "The study may have used other variants (e.g., wild-type) as controls, but this is not detailed in the abstract."
        },
        {
          "step": "3c. Correlate OddsPath",
          "judgment": "Not explicitly stated",
          "details": "The abstract mentions the A53T mutation's greater effect compared to E46K, suggesting a stronger statistical association."
        },
        {
          "step": "4a. Statistical analyses",
          "judgment": "Not explicitly stated",
          "details": "The abstract does not report p-values or effect sizes, but the A53T mutation's stronger effect implies statistical significance."
        },
        {
          "step": "4b. Control variant count",
          "judgment": "Unclear",
          "details": "The abstract does not specify the number of benign/pathogenic controls used in the study."
        },
        {
          "step": "4c. OddsPath correlation",
          "judgment": "Not applicable",
          "details": "No direct OddsPath value reported, but the A53T mutation's stronger effect implies a higher pathogenicity likelihood."
        }
      ],
      "strength": "PS3_supporting"
    },
    {
      "variant_string_id": "SNCA_Glu83Lys",
      "functional_evidence_aim": "Pathogenic",
      "steps": [
        {
          "step": "1. Define the disease mechanism",
          "judgment": "Yes",
          "details": "The Glu83Lys mutation increases polymerization but perturbs mature amyloid properties, suggesting functional disruption linked to disease."
        },
        {
          "step": "2. Evaluate assay applicability",
          "judgment": "Yes",
          "details": "The polymerization assay models the disease mechanism (amyloid formation) and is relevant to pathological outcomes."
        },
        {
          "step": "3a. Basic controls and replicates",
          "judgment": "Not explicitly stated",
          "details": "The abstract does not specify controls or replicates, but the study likely included wild-type and other variant comparisons."
        },
        {
          "step": "3b. Variant controls",
          "judgment": "Not explicitly stated",
          "details": "The study may have used other variants (e.g., wild-type) as controls, but this is not detailed in the abstract."
        },
        {
          "step": "3c. Correlate OddsPath",
          "judgment": "Not explicitly stated",
          "details": "The abstract mentions perturbed amyloid properties, suggesting functional disruption but no OddsPath calculation."
        },
        {
          "step": "4a. Statistical analyses",
          "judgment": "Not explicitly stated",
          "details": "The abstract does not report p-values or effect sizes, but the mutation's impact on amyloid properties implies statistical significance."
        },
        {
          "step": "4b. Control variant count",
          "judgment": "Unclear",
          "details": "The abstract does not specify the number of benign/pathogenic controls used in the study."
        },
        {
          "step": "4c. OddsPath correlation",
          "judgment": "Not applicable",
          "details": "No direct OddsPath value reported, but the mutation's impact on amyloid properties implies a higher pathogenicity likelihood."
        }
      ],
      "strength": "PS3_supporting"
    },
    {
      "variant_string_id": "SNCA_Glu83Ala",
      "functional_evidence_aim": "Pathogenic",
      "steps": [
        {
          "step": "1. Define the disease mechanism",
          "judgment": "Yes",
          "details": "The Glu83Ala mutation (substitution) increases polymerization, suggesting functional disruption linked to disease."
        },
        {
          "step": "2. Evaluate assay applicability",
          "judgment": "Yes",
          "details": "The polymerization assay models the disease mechanism (amyloid formation) and is relevant to pathological outcomes."
        },
        {
          "step": "3a. Basic controls and replicates",
          "judgment": "Not explicitly stated",
          "details": "The abstract does not specify controls or replicates, but the study likely included wild-type and other variant comparisons."
        },
        {
          "step": "3b. Variant controls",
          "judgment": "Not explicitly stated",
          "details": "The study may have used other variants (e.g., wild-type) as controls, but this is not detailed in the abstract."
        },
        {
          "step": "3c. Correlate OddsPath",
          "judgment": "Not explicitly stated",
          "details": "The abstract mentions increased polymerization, suggesting functional disruption but no OddsPath calculation."
        },
        {
          "step": "4a. Statistical analyses",
          "judgment": "Not explicitly stated",
          "details": "The abstract does not report p-values or effect sizes, but the mutation's impact on polymerization implies statistical significance."
        },
        {
          "step": "4b. Control variant count",
          "judgment": "Unclear",
          "details": "The abstract does not specify the number of benign/pathogenic controls used in the study."
        },
        {
          "step": "4c. OddsPath correlation",
          "judgment": "Not applicable",
          "details": "No direct OddsPath value reported, but the mutation's impact on polymerization implies a higher pathogenicity likelihood."
        }
      ],
      "strength": "PS3_supporting"
    }
  ]
}